Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 9.50
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 1.50 (15.789%)
Open: 10.25
High: 10.40
Low: 10.00
Prev. Close: 10.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Van Elle and Hargreaves Services post profit rises

Wed, 25th Jan 2023 14:43

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hargreaves Services PLC - Durham, England-based land, property and infrastructure development - In the half year to November 30, pretax profit jumps 80% to GBP18.7 million from GBP10.4 million a year prior. Revenue jumps 53% to GBP116.5 million from GBP76.1 million. Net asset value per share grows 31% to 603 pence from 462p. Lifts dividend by 7.1% to 3.0 pence per share from 2.8p. Expects that financial year 2023 results will be in line with market expectations. Meanwhile, Finance Director John Samuel steps down from his role on July 31. He will be replaced by Stephen Craigen a day later. Craigen has been financial controller at company since 2017.

----------

Van Elle Holdings PLC - Nottinghamshire-based geotechnical engineering contractor - In the six months to October 31, pretax profit climbs 74% to GBP3.3 million from GBP1.9 million a year prior. Revenue increases to GBP80.8 million from GBP60.1 million. Declares an interim dividend of 0.4p per share versus none a year ago. Net debt as at October 31 widens to GBP2.5 million from GBP2.0 million a year prior. Adds that current trading is in line with management's expectations. Says it is confident in achieving market expectations for financial year 2023, which it says are an underlying pretax profit of GBP5.3 million with a range of GBP5.2 million to GBP5.4 million. In August, the company had reported an underlying profit of GBP1.9 million.

----------

IOG PLC - North Sea-focused gas and infrastructure operator - Reports 2022 revenue before sales deductions of GBP79.6 million, compared to nothing in 2021 as 2022 was IOG's first year as producer. Gas output from March to December 31 was 27.4 million standard cubic feet per day. Average realised gas price was 203.5p per therm, which includes short-term price fixes. For January 2023, IOG notes a 319p per therm price fix for 30,000 therms per day is in place. Company aims to release its 2022 results during March. IOG notes that the UK North Sea Transition Authority is expected to make the first 33rd round license awards in the second quarter of 2023.

----------

Scancell Holdings PLC- Nottingham, England-based cancer immunotherapies developer - In the six months to October 31, turns to pretax loss of GBP4.1 million from a profit of GBP2.5 million a year prior. Development expenses widen to GBP4.9 million from GBP4.0 million as administrative expenses widen to GBP2.4 million from GBP1.9 million. Reports finance expense of GBP910,000 relating to revaluation of derivative liability, swung from a gain of GBP2.4 million a year earlier. Does not yet generate revenue. Meanwhile, gives an update on a study on a vaccine trial. 14 patients were enrolled and dosed in expansion phase of the cancer-focused Modi-1 trial, with no safety issues to date. Expands SCIB1 phase 2 combination trial to include doublet therapy, meaning patients will receive two agents, namely skin-cancer focused ipilimumab and nivolumab, which is used to treat several cancers. Says expansion leads to significantly increased recruitment rate. Notes that recruitment for its Covidity clinical trial in South Africa is complete. Expects safety and immunogenicity data from Covidity in the first quarter of 2023.

----------

SuperSeed Capital Ltd - venture capital for early-stage business-to-business technology companies in UK - Says in the fourth quarter of 2022, Fund II portfolio monthly recurring revenue grows 21%. Adds that for 2022, Fund II portfolio monthly recurring revenue rises three-fold. Expects Fund portfolio company revenue to more than double in 2023. "Looking ahead, SuperSeed continues to lean into artificial intelligence as the main tech driver for change. We expect continued strong revenue growth in the portfolio," the company says. Meanwhile, SuperSeed expects that the fund will invest in 5 to 10 more service as a software companies in 2023.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
24 Oct 2018 12:28

Oxford Technology VCTs Mostly Report Drop In Net Asset Value

LONDON (Alliance News) - The Oxford Technology-managed venture capital trusts reported interim results on Wednesday, with all but one see a drop in net asset value.Oxford Technology Venture

Read more
24 Oct 2018 10:43

WINNERS & LOSERS SUMMARY: Metro Bank Down Amid Mortgage Competition

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 0.9%. The bank reported a rise in third by

Read more
23 Oct 2018 15:59

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 24 OctoberIndigovisionBeeks FinancialReddePhoto-Me 25 & Smart 26 29 30

Read more
25 Sep 2018 11:51

Scancell Well Placed To Keep Pushing Forward Cancer Treatment Work

LONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC on Tuesday said it is well funded to progress its range of proposed cancer immunotherapies.Scancell is developing for based

Read more
18 Sep 2018 16:19

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 19 September KingfisherHalf Year ResultsBabcock InternationalTrading Year Year

Read more
24 Jul 2018 12:26

Hygea VCT Net Asset Value Shrinks In First Half On Portfolio Value

LONDON (Alliance News) - Hygea VCT PLC on Tuesday said net asset value decreased in the first half of its current financial year due to a fall in value of its AIM-listed portfolio in the venture a

Read more
23 May 2018 14:29

Scancell To Receive European Patent For Moditope Platform In June

LONDON (Alliance News) - Scancell Holdings PLC on Wednesday said it will secure a European patent for its Moditope immunotherapy platform in mid-June.The cancer treatment developer said the

Read more
8 May 2018 11:16

Scancell Holdings Raises GBP1.2 Million Via Share Open Offer (ALLISS)

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that it has raised GBP1.2 million through an open offer of 10.1 million shares at a price of 12.0 pence per share.Shares in the a

Read more
3 May 2018 13:43

Hygea VCT Increases NAV Per Share, Changes RBS Overdraft To Loan

LONDON (Alliance News) - Hygea VCT PLC said on Thursday its net present value per share increased in the recent quarter.At March 31, Hygea's NAV per share was 64.4p, up from 63.8p at of

Read more
18 Apr 2018 15:09

UPDATE: Scancell Raises GBP7.5 Million, Makes Antibody Acquisition (ALLISS)

LONDON (Alliance News) - Immunotherapy developer Scancell Holdings PLC said Wednesday that it raised GBP7.5 million via a placing of 57.4 million shares and a subscription of 5.0 million shares at

Read more
18 Apr 2018 11:44

Scancell Announces GBP8 Million Fundraise, Makes Antibody Acquisition (ALLISS)

LONDON (Alliance News) - Immunotherapy developer Scancell Holdings PLC said Wednesday that it will raise up to GBP8.0 million via equity issue and also announced a technology shares were down 20%

Read more
3 Apr 2018 11:02

Scancell Signs Manufacturing Agreement With PolyPeptide Group

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC said on Tuesday it has signed a manufacturing agreement with therapeutic peptide manufacturer the f T

Read more
19 Oct 2016 11:05

Oxford Technology Venture Capital Funds Suffer Value Drop

Read more
10 Oct 2016 11:42

Scancell to develop ImmunoBody lung cancer treatment

(ShareCast News) - Cancer immunotherapy development company Scancell Holdings announced on Monday its intention to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer in combination with a checkpoint inhibitor. The AIM-traded firm's board approved the decision based on the o

Read more
16 Sep 2016 14:24

Scancell Holdings widens full year loss on US investment

(ShareCast News) - Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, has reported a third consecutive full year loss due to the costs involved in its expansion in the US. The firm has seen a 3% increase in its operating loss over the last three years. The loss was

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.